Bridge Therapeutics

Bridge to a

Better Therapy

We separate pain from addiction

Bridge Therapeutics, Inc. is a development-stage pharmaceutical company pursuing FDA approval of BT 219, a better delivery of buprenorphine-naloxone for opioid use disorder (OUD), and approval of BT-205, a patented drug combination for the treatment of chronic pain in opioid-experienced patients (U.S. Patent #8410092).


To improve the healthcare of millions of patients through safer and more effective therapies for opioid use disorder (OUD) and chronic pain.

OUD patients should welcome BT-219’s superior delivery of buprenorphine-naloxone.

Chronic pain patients should transition from standard opioid therapy to BT-205 without withdrawal and without euphoria, which is the main reason for abusing pain killers.